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Dear Editor,
We read with great interest the article by Metin et al.1 dealing
with the possible correlation between hypersexuality and levetir-
acetam (LEV). Indeed, the authors reported a female patient with
epilepsy who experienced increased sexual drive after the addition
of LEV (2000 mg/day) to her ongoing carbamazepine (CBZ)
therapy.
Although the association between epilepsy and sexual-dys-
function (SD) has often been described, to date, the aetiology of SD-
related epilepsy remains uncertain, but likely to be multifactorial
involving neurological (type of epilepsy, age of onset, seizure
frequency), endocrine (effect of epileptiform activity on the
hypothalamic–pituitary–gonadal axis), iatrogenic (antiepileptic
drugs, antidepressant) psychiatric (anxiety and depression),
cognitive and psychosocial factors.2,3
In particular, liver enzyme-inducing antiepileptic drugs
(AEDs), i.e. phenobarbital, phenytoin, and carbamazepine, can
cause SD by decreasing bioactive testosterone, accelerating sexual
hormone metabolism, and stimulating binding hormone proteins
production.
Conversely, new AEDs, including topiramate, zonisamide,
oxcarbazepine, lamotrigine and pregabalin, are thought to cause
SD through complex and poorly understood mechanisms.4
Although Svalheim et al.5 have demonstrated that LEV
treatment apparently has no drug-speciﬁc sexual or endocrine
side effects in men or women aged 45 years, a few case reports are
emerging from the literature showing a possible correlation
between SD and LEV ingestion.
Indeed, alongside the interesting case of LEV-induced hyper-
sexuality by Metin et al., we have recently reported two young men
with epilepsy who experienced severe loss of libido and anhedonia
after LEV intake.6
Levetiracetam is a new AED exerting its antiepileptic effect
through multiple and poorly understood mechanisms of action.
Synaptic vesicle glycoprotein 2A vesicular membrane protein
appears to be the main pharmacological target, but several effects
on ion channels have been described, including blockade of high-
voltage-activated Ca2+ channels, modulation of K+ channels, and
enhancement of GABA- and glycine-gated currents. In particular,
LEV-induced inhibition of presynaptic P/Q-type calcium channels has
been demonstrated to increase brainstem serotonin concentration1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.01.003in mice, with a consequent imbalance in dopamine/serotonin rate
leading to alteration in emotion-related behaviour.7
Thus, since LEV did not appear to alter the sex hormonal proﬁle,
other possible pathomechanisms leading to SD should be
considered. Indeed, given that sexual desire and pleasure are
mainly related to CNS dopamine levels, it is hypothesizable that
LEV-induced loss of libido (as in the patient reported by our
group)6 or hypersexuality (as in the patient by Metin et al.1) may be
related to alterations in brain excitatory transmission (sexual drive
and arousal) by unbalancing the dopamine/serotonin ratio.
In conclusion, as individuals with epilepsy may not spontane-
ously complain of SD, we recommend a wide assessment of their
sexual function, because even new AEDs, including LEV, may cause
sexual disorders through complex and still poorly understood
neurobiological mechanisms.
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